Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. on July 14, 2010, reporting events that occurred on July 8, 2010. The filing addresses Item 5.02 regarding compensatory arrangements for certain officers. Note: The request metadata references "Capricor Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Nile Therapeutics, Inc."
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee of the Board of Directors authorized the following changes effective July 8, 2010:
- Stock Option Awards:
- Daron Evans (CFO): Awarded a 10-year option to purchase 200,000 shares at an exercise price of $0.301 per share. Vesting occurs in 12 equal quarterly installments over three years, starting September 30, 2010.
- Hsiao Lieu, M.D. (VP, Clinical Research): Awarded a 10-year option to purchase 100,000 shares at an exercise price of $0.301 per share. Vesting occurs in 4 equal quarterly installments over one year, starting September 30, 2010.
- Salary Increase: Mr. Evans' annual base salary was increased from $200,000 to $250,000, effective July 15, 2010.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The stock option awards were made pursuant to the Company's Amended and Restated 2005 Stock Option Plan.
Investor Verification Checklist
- Verify the total number of shares reserved under the 2005 Stock Option Plan to assess dilution impact.
- Confirm the current market price of Nile Therapeutics common stock relative to the $0.301 exercise price.
- Review the Company's cash position to ensure it can sustain the increased annual salary expense for the CFO.
- Check for any subsequent filings regarding the vesting schedule or performance conditions attached to these awards.